Answers are grounded in this paper and cite their sources.
// Jie Yin 1, * , Lan Wang 2, * , Ji-Min Zhu 1 , Qian Yu 1 , Ru-Yi Xue 1 , Ying Fang 1 , Yi-An Zhang 1 , Yan-Jie Chen 1 , Tao-Tao Liu 1 , Ling Dong 1 , Xi-Zhong Shen 1, 3, 4 1 Department of Gastroenterology, Zhongshan Hospital of Fudan University, Shanghai, China 2 Department of Biochemistry and Molecular Biology, Shanghai Medical College of Fudan University, Shanghai, China 3 Shanghai Institute of Liver Diseases, Zhongshan Hospital of Fudan University, Shanghai, China 4 Key Laboratory of Medical Molecular Virology, Shanghai Medical College of Fudan University, Shanghai, China * These authors have contributed equally to this work Correspondence to: Xi-Zhong Shen, e-mail: shen.xizhong@zs-hospital.sh.cn Ling Dong, e-mail: dong.ling@zs-hospital.sh.cn Keywords: liver cancer, tumor progression, ubiquitination, signaling pathway Received: July 10, 2015 Accepted: February 20, 2016 Published: March 03, 2016 ABSTRACT Pre-mRNA processing factor 19 (Prp19) is involved in many cellular events including pre-mRNA processing and DNA damage response. However, the pathological role of Prp19 in hepatocellular carcinoma (HCC) is still elusive. Here, we reported that Prp19 was increased in most HCC tissues and HCC cell lines, and its overexpression in HCC tissues was positively correlated with vascular invasion, tumor capsule breakthrough and poor prognosis. Prp19 potentiated migratory and invasive abilities of HCC cells in vitro and in vivo . Furthermore Prp19 facilitated Twist1-induced epithelial-mesenchymal transition. Mechanistic insights revealed that Prp19 directly binded with TGF-β-activated kinase1 (TAK1) and promoted the activation of p38 mitogen-activated protein kinase (MAPK), preventing Twist1 from degradation. Finally Prp19/p38 MAPK/Twist1 axis was attested in nude mice xenografts and HCC patient specimens. This work implies that the gain of Prp19 is a critical event during the progression of HCC, making it a promising target for malignancies with aberrant Prp19 expression.
No takes yet. Share an insight, caveat, or question.
Yin et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: